WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has
priced an offering of €500 million aggregate principal amount of 1.450%
senior notes due 2027 at an issue price of 98.824% of the principal
The issuance of the notes is expected to close on or about March 16,
2017, subject to customary closing conditions. The notes will pay
interest on an annual basis.
Thermo Fisher intends to use approximately $508 million of the net
proceeds of the offering to redeem all of the outstanding $500 million
aggregate principal amount of its 1.850% senior notes that mature on
January 15, 2018 and to pay accrued interest, fees and expenses
associated with the redemption. Thermo Fisher intends to use any
remaining net proceeds for general corporate purposes.
The joint book-running managers for the offering are Credit Suisse
Securities (Europe) Limited and HSBC Bank plc.
The offering is being made pursuant to an effective registration
statement on Form S-3, as amended by the post-effective amendment
thereto (including a prospectus), filed with the U.S. Securities and
Exchange Commission (the “SEC”). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the offering and the other documents
that the company has filed with the SEC for more complete information
about the company and this offering. These documents are available at no
charge by visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, Thermo Fisher, the underwriters or any dealer
participating in this offering will arrange to send you the prospectus
if you request it by calling Credit Suisse Securities (Europe) Limited
toll-free at 1-800-221-1037, or by calling HSBC Bank plc toll-free at
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any offer,
solicitation or sale of the notes in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements about the company’s intended
use of proceeds. These statements involve a number of risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results, including risks and uncertainties
relating to capital markets conditions and completion of the offering.
Additional important factors and information regarding Thermo Fisher’s
business that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in the
prospectus and prospectus supplement dated March 7, 2017 related to the
offering, which is on file with the SEC and available in the “Investors”
section of our website under the heading “SEC Filings,” and the
documents incorporated by reference into the prospectus and prospectus
supplement. While we may elect to update forward-looking statements at
some point in the future, we specifically disclaim any obligation to do
so, even if circumstances change and, therefore, you should not rely on
these forward-looking statements as representing our views as of any
date subsequent to today.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307006486/en/
Source: Thermo Fisher Scientific Inc.